Drugs / Visonac
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01347879 | May 2011 → Apr 2012 | acne | Photocure | Completed | Met primary |
| Phase 2 | NCT01160848 | Aug 2010 → Jan 2011 | acne | Photocure | Completed | No outcome recorded |
| Phase 2 | NCT00933543 | Aug 2009 → Mar 2010 | acne | Photocure | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2015-12-14 | Photocure | Results Photocure: Visonac® data published in the British Journal of Dermatology photocure.com ↗
Results showed Visonac ® produced a statistically significant reduction in inflammatory lesions and an overall improvement in acne severity. |
| 2012-05-31 | Photocure | Results PHOTOCURE: VISONAC® PHASE 2b TRIAL RESULTS - INVITATION TO PRESENTATION AND WEBCAST photocure.com ↗
Photocure ASA (OSE: PHO), is pleased to announce the results of its Phase 2b study for Visonac, a novel topical treatment under development for moderate to severe acne. |
| 2012-05-31 | Photocure | Results PHOTOCURE: PRESENTATION OF VISONAC® PHASE 2b TRIAL RESULTS photocure.com ↗
Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, will present its positive results from the Phase 2b study for Visonac, a novel topical treatment under development for moderate to severe acne. |
| 2012-05-31 | Photocure | Results PHOTOCURE ANNOUNCES POSITIVE RESULTS OF PHASE 2B STUDY EVALUATING VISONAC® IN ACNE photocure.com ↗
In this study, Visonac showed a statistically significant reduction in inflammatory lesions and overall improvement in acne severity. |
| 2010-05-28 | Photocure | Results Photocure announces results from phase II study in acne with Visonac(TM) photocure.com ↗
The results showed a median reduction of 39.8% for the inflammatory lesions and 36.3% for the non-inflammatory lesions after Visonac(TM). |
All press releases naming this drug 10 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Visonac | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01160848 ↗ |
| Route | Topical | “Cream application followed by illumination with red light.” NCT00933543 ↗ |